Skip to main content
Ann Navar, MD, Cardiology, Dallas, TX

Ann Marie Navar MD PhD, FACC, FAHA, FASCP

Cardiology•Dallas, TX

Preventive Cardiology

Physician

Join to View Full Profile

  • 5323 Harry Hines BoulevardDallas, TX 75390

  • Phone+1 214-633-5555

  • Fax+1 214-645-6757

Dr. Navar is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Navar's Full ProfileAlready have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 2013 - 2016
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine/Pediatrics, 2009 - 2013
  • Duke University School of Medicine
    Duke University School of MedicineClass of 2009

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2020 - 2026
  • NC State Medical License
    NC State Medical License 2009 - 2021
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Journal Articles

  • Choosing an Initial Therapeutic Approach for Hypertension—Time for a Fixed-Dose Combination First?  
    Ann Marie Navar, Thomas J Wang, JAMA Cardiology
  • Heroism in the Face of the COVID-19 Pandemic  
    Ajay J Kirtane, Ann Marie Navar, JAMA Cardiology
  • Moving Beyond Regression Techniques in Cardiovascular Risk Prediction: Applying Machine Learning to Address Analytic Challenges  
    Ann Navar, MD, European Heart Journal

Abstracts/Posters

  • [Board 414] Triglycerides as a Risk Factor For Coronary Heart Disease: What Measure and What Cutoff?
    Ann Navar, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/18/2019

Lectures

  • Deep Dive II 
    2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019

Authored Content

  • How Real-World Data Augments What We Know About SGLT-2 Inhibitors for Cardiovascular Risk ReductionSeptember 2020
  • Choosing an Initial Therapeutic Approach for Hypertension—Time for a Fixed-Dose Combination First?July 2020
  • Heroism in the Face of the COVID-19 PandemicJune 2020

Press Mentions

  • CORALreef Lipids: Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in High-Risk Patients
    CORALreef Lipids: Oral PCSK9 Inhibitor Enlicitide Reduces LDL-C in High-Risk PatientsFebruary 10th, 2026
  • Cardiologist Impressed by Experimental Pill That Significantly Lowers Cholesterol
    Cardiologist Impressed by Experimental Pill That Significantly Lowers CholesterolFebruary 6th, 2026
  • Experimental Cholesterol-Lowering Pill May Offer New Option for Millions
    Experimental Cholesterol-Lowering Pill May Offer New Option for MillionsFebruary 4th, 2026

Other Languages

  • Spanish

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Ann Navar, Dr. Ann Navar, MD, Dr. A Navar, Dr. Ann Marie Navar